[DOI] [PMC free article] [PubMed] [Google Scholar] 166.Zhang J et al
New England Journal Of Medicine *In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, those on semaglutide lost on average 14.9% of their weight as opposed to 2% of the placebo group
"GLP-1 medications can increase the risk of dehydration because you may drink less, experience nausea or develop vomiting or diarrhea," Duah says
If there isnt enough glutathione in the cells, free radicals can run rampant and cause chaos at the cellular level
The pH of compounded tirzepatide solutions also contributes to injection site discomfort
This effect proves to be greater for long-acting compared to short-acting formulations and is more pronounced, in comparative studies, with injective semaglutide at a dosage of 1 mg once weekly, which reduces HbA1c by 1.8% compared to 1.21.4% of other injective long-acting GLP-1 RAs and 1.1% of oral semaglutide (Figure 1A) [1, 2]